Clinical trial
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma…
NCT01028222 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT01028222 |
|---|---|
| Title | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation |
| Official title | The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation |
| Acronym | TEAM |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Nilotinib, DTIC |
| Enrollment | 55 |
| Start date | Jun 1, 2010 |
| Primary completion | Dec 1, 2014 |
| Completion | Dec 1, 2014 |
| First posted | Dec 9, 2009 |
| Last update posted | Dec 30, 2015 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, China, Germany, Italy, Netherlands, Singapore, Spain, Sweden and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: